On the U.S. market since 2006, Allergan’s BIOCELL textured breast implants have been linked to a severely increased risk of breast implant-related anaplastic large cell lymphoma (BIA-ALCL). Other implants on the market with smooth surfaces do not carry the same risks. In July 2019, the Food and Drug Administration (FDA) requested that Allergan recall its textured breast implant products after reports of cancer and, in some cases, death.
BIA-ALCL is not a typical breast cancer, but rather a cancer of the lymphatic system. It can form in the capsule surrounding the breast implant. Symptoms of this dangerous disease include pain, swelling, and lumps around the breast. Doctors can diagnose BIA-ALCL by testing fluid for biomarker CD30. If CD30 is present, your doctor will probably recomment that you have the BIOCELL textured breast implants removed, along with removal of the surrounding scar capsule.
The list of Allergan BIOCELL products subject to the recall is extensive and can be found by clicking here. If you or a loved one has experienced symptoms of swelling and pain after receiving these products, seek medical treatment and contact Egerton Law to discuss your legal rights.